Drug Trial Radar · NCT04539496
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
402
Actual
Start
May 22, 2018
Primary completion
Jul 31, 2023
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes single agent/combination dose exploration study and the phase II study. The primary purpose of the dose exploration study is to determine the maximum tolerated dose(MTD)/recommended phase II dose(RP2D) of XZP-3287 and assess its safety and preliminary efficacy in solid tumor patients. The phase II study aims to explore the efficacy and safety profiles of XZP-3287 as a single- agent in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.
Conditions
- Metastasis Solid Tumors
- Advanced Breast Cancer
Interventions
XZP-3287Drug
* 20-560 mg QD, oral * 240-480 mg BID, oral
XZP-3287;Letrozole;Anastrozole;FulvestrantDrug
XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)
XZP-3287Drug
480 mg BID, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single agent and combination dose exploration study:AE evaluationTime frame: Up to 30 days after the end of treatment
- The phase II study:Objective response rate (ORR) assessed by Independent Review Committee (IRC)Time frame: From baseline to the date of first documentation of progression or death , whichever came first, assessed approximately up to 2 years after the last entered participant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.